Diuretic resistance in cardiorenal syndrome: mechanisms, monitoring and phenotype-tailored management

Can we break the cycle of Diuretic Resistance?

What do you do when the "gold standard" treatment for your congested patient simply stops working? Diuretic resistance (DR) affects up to one-third of patients with heart failure, turning a routine clinical task into a high-stakes battle against prolonged hospitalization and mortality. In this episode, we dive into a comprehensive narrative review that moves beyond simple drug escalation to offer a sophisticated, phenotype-driven roadmap for the modern clinician. The authors synthesize data from nearly 100 pivotal studies to dismantle the "one-size-fits-all" approach to decongestion. We explore the multifactorial drivers of resistance—from chloride depletion and neurohormonal "braking" to the structural remodeling of the nephron itself. Rather than just pushing more furosemide, the study highlights how early monitoring of urinary sodium and the use of point-of-care ultrasound (POCUS) can identify failure before it becomes entrenched. The real "so what" for your next shift lies in the study’s focus on four challenging phenotypes: Right Heart Failure, advanced CKD, Obesity, and Frailty. We discuss why chloride repletion might be your secret weapon, how metabolic therapies like GLP-1 RAs are changing the game for obese patients, and why a small rise in creatinine shouldn't always scare you away from aggressive diuresis. Tune in to learn how to tailor your decongestion strategy to the patient in front of you and finally get ahead of the curve on diuretic resistance.